Talks
ZANU+Len in R/R DLBCL
June 11, 2026
Duvelisib/Ven in CLL & RT
June 11, 2026
Update of SUNMO Trial
June 4, 2026
Odronextamab-CHOP in LBCL
June 4, 2026
BSAs in Pretreated FL: Real World
June 4, 2026
Golcadomide in Aggressive BCL
June 4, 2026
CD30 Expression in 3L Lymphoma
May 20, 2026
Mosunetuzumab in Untreated LBCL
May 20, 2026
Long-Term Follow-Up of LBCL
May 8, 2026
BV/Nivo/Ipi in Relapsed HL
May 8, 2026
ctDNA in Hodgkin Lymphoma
May 8, 2026
ctDNA in FL
May 8, 2026
Real World Acalabrutinib in CLL
May 8, 2026
Tucidinostat in DEL LBCL
April 29, 2026
Acalabrutinib in WM
April 23, 2026
Zanubrutinib vs AV in CLL
April 23, 2026
BV-Nivo/Dox/DTIC in Early Stage HL
April 16, 2026
Skin Cancers in CLL
April 16, 2026
Pirtobrutinib in Marginal Zone
April 16, 2026
Clonal Hematopoiesis in CLL
March 26, 2026
Nivo-AVD in Hodgkin
March 26, 2026
Venetoclax Retreatment
March 19, 2026
Patient BTKi Preferences
March 19, 2026
Mosunetuzumab in Richter’s
March 19, 2026
Zanubrutinib in 17p-CLL
March 9, 2026
Hypertension in CLL
March 9, 2026
BTKi Discontinuation Rates in CLL
March 9, 2026
Withdrawal of Tazemetostat
March 9, 2026
CART for CNS Lymphoma
February 23, 2026
Acalabrutinib in Older and/or Frail Patients with CLL
February 6, 2026
CNS Involvement in CLL
February 2, 2026
Zanu + Ven in Poor Risk CLL
February 2, 2026
LOTIS-7 Study in DLBCL
February 2, 2026
Zanu/Sonrotoclax in CLL
February 2, 2026
ROSEWOOD Study Analysis
February 2, 2026
inMIND Trial
February 2, 2026
Epcoritamab in CLL
February 2, 2026
AMPLIFY Phase III Trial
February 2, 2026
Epcoritamab in elderly LBCL
January 19, 2026
Lisaftoclax in CLL
January 19, 2026
Rocbrutinib
January 19, 2026
R-glofit-pola in elderly LBCl
January 19, 2026
Resistance to Pirtobrutinib
January 17, 2026
BGB-16673 in CLL
January 17, 2026
Limited duration acalabrutinib
January 17, 2026
Pirtobrutinib vs BR in CLL
January 17, 2026
Bexobrutideg in CLL
January 17, 2026
Pirtobrutinib vs Ibrutinib in CLL
January 16, 2026
Close button
Why are you reporting this TALK?